Relay Therapeutics, Inc. (RLAY)

6,66 +0,14 (+2,15 %) À la clôture : 04:00PM EDT

Relay Therapeutics, Inc.

399 Binney Street
2nd Floor
Cambridge, MA 02139
United States
617 370 8837
https://www.relaytx.com

Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 323

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Mr. Alexis A. Borisy A.M.	Co-Founder & Independent Chairman	92,5k	S.O.	1972
Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS	CEO, President & Director	1,08M	1,96M	1974
Dr. Mark Murcko Ph.D.	Co-Founder & Director	60k	S.O.	1960
Mr. Thomas Catinazzo	Chief Financial Officer	663,99k	S.O.	1977
Mr. Brian R. Adams J.D.	Chief Legal Officer & Secretary	627,72k	S.O.	1974
Mr. Peter Rahmer	Chief Corporate Development Officer	626,62k	S.O.	S.O.
Dr. Donald A. Bergstrom M.D., Ph.D.	President of Research & Development	1,37M	S.O.	1972
Dr. Deborah Palestrant M.B.A., Ph.D.	Vice President of Corporate Development & Strategy	S.O.	S.O.	S.O.
Mr. Jim Watters Ph.D.	Chief Scientific Officer of Late Research	S.O.	S.O.	S.O.
Dr. Beni B. Wolf M.D., Ph.D.	Chief Medical Officer & Head of Precision Medicine	S.O.	S.O.	S.O.

Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Relay Therapeutics, Inc. en date du 29 avril 2024 est 7. Les scores principaux sont Audit : 5; Société : 7; Droits des actionnaires : 8; Compensation : 8.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.